Slone Dobyns
About Slone Dobyns
Slone Dobyns is a Senior Sales Representative in the ADHD Division at Supernus Pharmaceuticals, Inc., where he has worked since 2021. He has a background in sales within the pharmaceutical industry and holds a Bachelor of Arts in Organizational Communication from the University of Missouri-Columbia.
Work at Supernus Pharmaceuticals
Slone Dobyns has been employed at Supernus Pharmaceuticals, Inc. since 2017. Initially, he served as a Professional Sales Representative in the CNS Division from 2017 to 2019. He then transitioned to the role of Senior Sales Representative in the CNS Division from 2019 to 2021. Since 2021, he has been working as a Senior Sales Representative in the ADHD Division. His tenure at Supernus Pharmaceuticals highlights his experience in pharmaceutical sales, particularly in the areas of central nervous system and ADHD treatments.
Previous Experience in Sales
Before joining Supernus Pharmaceuticals, Slone Dobyns worked at Southern Glazer's Wine & Spirits as a Sales Representative in the DMH Division from 2016 to 2017. This role contributed to his foundational skills in sales and customer relationship management. His diverse experience in sales across different industries has equipped him with a broad understanding of market dynamics and client needs.
Education and Expertise
Slone Dobyns earned a Bachelor of Arts (B.A.) in Organizational Communication from the University of Missouri-Columbia, where he studied from 2011 to 2015. His educational background in organizational communication provides him with insights into effective communication strategies and interpersonal skills, which are essential in sales and client interactions.
Career Progression
Slone Dobyns has demonstrated a steady career progression in the sales field. His journey began at Southern Glazer's Wine & Spirits, followed by a series of roles at Supernus Pharmaceuticals, where he advanced from a Professional Sales Representative to a Senior Sales Representative. This progression reflects his commitment to the pharmaceutical industry and his ability to adapt to different product divisions.